U.S. Pharmaceuticals & Biotech High Return On Equity, Low Debt

Gilead Sciences

Market Cap: US$166.8b

A biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Illumina

Market Cap: US$21.8b

Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.

Exelixis

Market Cap: US$12.6b

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

ACADIA Pharmaceuticals

Market Cap: US$3.6b

A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.

ADMA Biologics

Market Cap: US$1.9b

A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

Innoviva

Market Cap: US$1.7b

Operates as a biopharmaceutical company in the United States and internationally.

Theravance Biopharma

Market Cap: US$843.9m

A biopharmaceutical company, develops and commercializes medicines in the United States.

CorMedix

Market Cap: US$626.0m

A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.

Abeona Therapeutics

Market Cap: US$310.1m

A commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.

Compugen

Market Cap: US$264.8m

A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.

Oramed Pharmaceuticals

Market Cap: US$161.4m

Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.

Vaxart

Market Cap: US$156.0m

A clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform.